These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29643855)

  • 21. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.
    Mayerhofer M; Gleixner KV; Hoelbl A; Florian S; Hoermann G; Aichberger KJ; Bilban M; Esterbauer H; Krauth MT; Sperr WR; Longley JB; Kralovics R; Moriggl R; Zappulla J; Liblau RS; Schwarzinger I; Sexl V; Sillaber C; Valent P
    J Immunol; 2008 Apr; 180(8):5466-76. PubMed ID: 18390729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.
    Jin Y; Lu Z; Cao K; Zhu Y; Chen Q; Zhu F; Qian C; Pan J
    Mol Cancer Ther; 2010 Jan; 9(1):211-23. PubMed ID: 20053766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.
    Saleh R; Wedeh G; Herrmann H; Bibi S; Cerny-Reiterer S; Sadovnik I; Blatt K; Hadzijusufovic E; Jeanningros S; Blanc C; Legarff-Tavernier M; Chapiro E; Nguyen-Khac F; Subra F; Bonnemye P; Dubreuil P; Desplat V; Merle-Béral H; Willmann M; Rülicke T; Valent P; Arock M
    Blood; 2014 Jul; 124(1):111-20. PubMed ID: 24677542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. c-Kit and c-kit mutations in mastocytosis and other hematological diseases.
    Boissan M; Feger F; Guillosson JJ; Arock M
    J Leukoc Biol; 2000 Feb; 67(2):135-48. PubMed ID: 10670573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.
    Hoermann G; Gleixner KV; Dinu GE; Kundi M; Greiner G; Wimazal F; Hadzijusufovic E; Mitterbauer G; Mannhalter C; Valent P; Sperr WR
    Allergy; 2014 Jun; 69(6):810-3. PubMed ID: 24750133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
    Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
    Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.
    Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS
    Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
    Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.
    Qin Z; Dai L; Trillo-Tinoco J; Senkal C; Wang W; Reske T; Bonstaff K; Del Valle L; Rodriguez P; Flemington E; Voelkel-Johnson C; Smith CD; Ogretmen B; Parsons C
    Mol Cancer Ther; 2014 Jan; 13(1):154-64. PubMed ID: 24140934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis.
    Greiner G; Witzeneder N; Klein K; Tangermann S; Kodajova P; Jaeger E; Ratzinger F; Gerner MC; Jawhar M; Baumgartner S; Fruehwirth K; Schmetterer KG; Zuber J; Gleixner KV; Mayerhofer M; Schwarzinger I; Simonitsch-Klupp I; Esterbauer H; Baer C; Walter W; Meggendorfer M; Strassl R; Haferlach T; Hartmann K; Kenner L; Sperr WR; Reiter A; Sexl V; Arock M; Valent P; Hoermann G
    Blood; 2024 Mar; 143(11):1006-1017. PubMed ID: 38142424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.
    Hoermann G; Cerny-Reiterer S; Perné A; Klauser M; Hoetzenecker K; Klein K; Müllauer L; Gröger M; Nijman SM; Klepetko W; Valent P; Mayerhofer M
    Am J Pathol; 2011 May; 178(5):2344-56. PubMed ID: 21457934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A transgenic zebrafish model expressing KIT-D816V recapitulates features of aggressive systemic mastocytosis.
    Balci TB; Prykhozhij SV; Teh EM; Da'as SI; McBride E; Liwski R; Chute IC; Leger D; Lewis SM; Berman JN
    Br J Haematol; 2014 Oct; 167(1):48-61. PubMed ID: 24989799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KIT D816V is dimerization-independent and activates downstream pathways frequently perturbed in mastocytosis.
    Rajan V; Prykhozhij SV; Pandey A; Cohen AM; Rainey JK; Berman JN
    Br J Haematol; 2023 Sep; 202(5):960-970. PubMed ID: 35245395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?
    Akin C; Arock M; Valent P
    J Allergy Clin Immunol; 2022 Jun; 149(6):1912-1918. PubMed ID: 35487307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IgE-dependent activation of sphingosine kinases 1 and 2 and secretion of sphingosine 1-phosphate requires Fyn kinase and contributes to mast cell responses.
    Olivera A; Urtz N; Mizugishi K; Yamashita Y; Gilfillan AM; Furumoto Y; Gu H; Proia RL; Baumruker T; Rivera J
    J Biol Chem; 2006 Feb; 281(5):2515-25. PubMed ID: 16316995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
    Shomali W; Gotlib J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.
    Harir N; Boudot C; Friedbichler K; Sonneck K; Kondo R; Martin-Lannerée S; Kenner L; Kerenyi M; Yahiaoui S; Gouilleux-Gruart V; Gondry J; Bénit L; Dusanter-Fourt I; Lassoued K; Valent P; Moriggl R; Gouilleux F
    Blood; 2008 Sep; 112(6):2463-73. PubMed ID: 18579792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis.
    Grootens J; Ungerstedt JS; Ekoff M; Rönnberg E; Klimkowska M; Amini RM; Arock M; Söderlund S; Mattsson M; Nilsson G; Dahlin JS
    EBioMedicine; 2019 May; 43():150-158. PubMed ID: 30975542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.